Scholarlink

Background <p>Ruxolitinib cream (1.5%) has demonstrated efficacy and safety in patients aged ≥&#xa0;2 years with mild-to-moderate atopic dermatitis.</p> Objective <p>We aimed to further investigate the safety and efficacy of ruxolitinib cream in adolescents with atopic dermatitis in an open-label study.</p> Methods <p>Patients aged 12–17&#xa0;years with atopic dermatitis, an Investigator’s Global Assessment score of 2/3, and 3–20% affected body surface area applied twice-daily 1.5% ruxolitinib cream for an 8-week continuous treatment period, followed by a 44-week long-term safety period in which ruxolitinib cream was applied twice daily as needed. Safety was the primary endpoint. Secondary endpoints included plasma trough concentrations of ruxolitinib. Affected body surface area, ≥&#xa0;75% improvement from baseline in Eczema Area and Severity Index, achievement of Investigator’s Global Assessment score of 0/1, and ≥&#xa0;4-point improvement from baseline in the itch Numerical Rating Scale were exploratory endpoints.</p> Results <p>Of 103 patients, 59.2% had a baseline Investigator’s Global Assessment of 3. Mean baseline body surface area and Eczema Area and Severity Index scores were 8.9% and 6.4, respectively. Over 52 weeks, 42 patients (40.8%) had treatment-emergent adverse events, most commonly upper respiratory tract infection (10.7%) and nasopharyngitis (8.7%). Three patients (2.9%) had grade ≥&#xa0;3 treatment-emergent adverse events; all were considered unrelated to treatment by the investigator. Steady-state ruxolitinib plasma concentrations during the continuous treatment period were low (geometric mean [geometric coefficient of variation], 14.2 [169] nM), consistent with the lack of observed treatment-emergent adverse events associated with systemic Janus kinase inhibition. Clinical improvements occurred during the continuous treatment period and were maintained or improved with as-needed treatment through the long-term safety period to week 52 (mean affected body surface area, 1.3%; ≥&#xa0;75% improvement from baseline in Eczema Area and Severity Index, 87.0%; Investigator’s Global Assessment 0/1, 82.6%; ≥&#xa0;4-point improvement from baseline in&#xa0;itch Numerical Rating Scale, 41.7%).</p> Conclusions <p>Ruxolitinib cream (1.5%) was well tolerated and efficacious with long-term as-needed use in adolescents with mild-to-moderate atopic dermatitis, consistent with safety and efficacy findings reported in previous phase III studies in adolescents and adults.</p> Clinical Trial Registration <p>Clinicaltrials.gov identifier, NCT05456529 (registered 13 July, 2022).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label Study

  • 期刊论文

  • 发表日期：

    2026年5月27日

查看全文
  • Joel C. Joyce,
  • H. Chih-ho Hong,
  • Dareen D. Siri,
  • Darryl Toth,
  • Howard Kallender,
  • YuTzu Kuo,
  • Diana Stefani-Hunyady,
  • Kim A. Papp

摘要

Background

Ruxolitinib cream (1.5%) has demonstrated efficacy and safety in patients aged ≥ 2 years with mild-to-moderate atopic dermatitis.

Objective

We aimed to further investigate the safety and efficacy of ruxolitinib cream in adolescents with atopic dermatitis in an open-label study.

Methods

Patients aged 12–17 years with atopic dermatitis, an Investigator’s Global Assessment score of 2/3, and 3–20% affected body surface area applied twice-daily 1.5% ruxolitinib cream for an 8-week continuous treatment period, followed by a 44-week long-term safety period in which ruxolitinib cream was applied twice daily as needed. Safety was the primary endpoint. Secondary endpoints included plasma trough concentrations of ruxolitinib. Affected body surface area, ≥ 75% improvement from baseline in Eczema Area and Severity Index, achievement of Investigator’s Global Assessment score of 0/1, and ≥ 4-point improvement from baseline in the itch Numerical Rating Scale were exploratory endpoints.

Results

Of 103 patients, 59.2% had a baseline Investigator’s Global Assessment of 3. Mean baseline body surface area and Eczema Area and Severity Index scores were 8.9% and 6.4, respectively. Over 52 weeks, 42 patients (40.8%) had treatment-emergent adverse events, most commonly upper respiratory tract infection (10.7%) and nasopharyngitis (8.7%). Three patients (2.9%) had grade ≥ 3 treatment-emergent adverse events; all were considered unrelated to treatment by the investigator. Steady-state ruxolitinib plasma concentrations during the continuous treatment period were low (geometric mean [geometric coefficient of variation], 14.2 [169] nM), consistent with the lack of observed treatment-emergent adverse events associated with systemic Janus kinase inhibition. Clinical improvements occurred during the continuous treatment period and were maintained or improved with as-needed treatment through the long-term safety period to week 52 (mean affected body surface area, 1.3%; ≥ 75% improvement from baseline in Eczema Area and Severity Index, 87.0%; Investigator’s Global Assessment 0/1, 82.6%; ≥ 4-point improvement from baseline in itch Numerical Rating Scale, 41.7%).

Conclusions

Ruxolitinib cream (1.5%) was well tolerated and efficacious with long-term as-needed use in adolescents with mild-to-moderate atopic dermatitis, consistent with safety and efficacy findings reported in previous phase III studies in adolescents and adults.

Clinical Trial Registration

Clinicaltrials.gov identifier, NCT05456529 (registered 13 July, 2022).